Skip to content

Enterprise value at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$158.92B-2.6%
Pfizer logo
PfizerPFE
$222.4B+9.2%
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
$109.92B-9.5%
Incyte logo
IncyteINCY
$15.31B+55.9%
BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
$9.22B-29.3%
Disc Medicine logo
Disc MedicineIRON
$2.38B+46.7%

Other financials

Income statement

See full
Revenue$20.7M+138%
Gross profit$19.4M+154%
Operating income-$110.0M-3.2%
Net income-$99.1M-11.0%
EPS (diluted)-$1.69-9.0%

Balance sheet

See full
Cash & equivalents$113.6M+43.9%
Total debt$35.7M-32.5%
Total equity$1.1B-24.4%
Total assets$1.2B-23.8%

Cash flow

See full
Operating cash flow-$118.9M-6.7%
CapEx$769.0K+0.4%
Free cash flow-$119.7M-6.6%

Valuation

See full
Market cap$2.12B+18.1%
P/S32.1×-16.4×

Profitability

See full
Gross margin90%+2.5pp
Operating margin-720%-204pp
Net margin-639.8%
FCF margin-582.5%-185pp

Returns & leverage

See full
Return on equity-32.8%
Debt / equity0.0×
Current ratio14.2×-4.3×

Where this comes from

Calculated from Agios Pharmaceuticals’s reported figures.

The official record: Agios Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Agios Pharmaceuticals's enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Agios Pharmaceuticals's enterprise value?
Agios Pharmaceuticals (AGIO) reported enterprise value of $1.9B in Q1 2026.
How has Agios Pharmaceuticals's enterprise value changed year-over-year?
Agios Pharmaceuticals's enterprise value increased by 15.2% year-over-year, from $1.65B to $1.9B.
What is the long-term trend for Agios Pharmaceuticals's enterprise value?
Over 5 years (2020 to 2025), Agios Pharmaceuticals's enterprise value has grown at a -8.0% compound annual growth rate (CAGR), from $2.33B to $1.54B.
What does enterprise value mean?
Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.